Children with RMDs not at high risk for severe COVID-19, study findsApril 13, 2022PediatricsCOVID-19 UpdatesRheumatoid ArthritisLupus & Connective Tissue Diseases
Severe obesity reduces responses to TNF inhibitors and non-TNF biologics to similar extentMarch 24, 2022Rheumatoid Arthritis
Drug survival study looks at what lasts longest in RA, axSpA, PsA, and psoriasisMarch 11, 2022SpondyloarthropathiesRheumatoid ArthritisPsoriatic ArthritisAnkylosing spondylitis
Updated perioperative guidance says when to hold antirheumaticsMarch 4, 2022Rheumatoid ArthritisSpondyloarthropathiesPsoriatic ArthritisLupus & Connective Tissue DiseasesAnkylosing spondylitisOrthopedics
Treat-to-target in RA: Questions remain about adoption, measurementFebruary 22, 2022Rheumatoid Arthritis
Patients are interrupting DMARD use well into the COVID-19 pandemicFebruary 17, 2022COVID-19 UpdatesRheumatoid ArthritisPsoriatic ArthritisLupus & Connective Tissue Diseases
Dietary recommendations for inflammatory rheumatic diseasesFebruary 10, 2022Rheumatoid ArthritisPsoriatic ArthritisAnkylosing spondylitisSpondyloarthropathies
Boxed warning for JAK inhibitors belies their durability in real-world registry studiesFebruary 9, 2022Rheumatoid Arthritis
Lilly calls it quits on baricitinib’s development for lupusJanuary 28, 2022Lupus & Connective Tissue DiseasesRheumatoid Arthritis
Rituximab and COVID-19 vaccines: Studies begin to answer key questionsJanuary 21, 2022COVID-19 UpdatesRheumatoid ArthritisLupus & Connective Tissue Diseases
Proactive infliximab monitoring found best for sustaining control of inflammatory diseasesJanuary 10, 2022Rheumatoid ArthritisPsoriatic ArthritisAnkylosing spondylitisSpondyloarthropathies
Low-dose rituximab may keep RA disease activity low in respondersNovember 19, 2021Rheumatoid Arthritis
Long-term glucocorticoids in RA linked to increased cardiovascular riskNovember 17, 2021Rheumatoid Arthritis
Tofacitinib postmarketing trial data shed light on JAK inhibitor risksNovember 16, 2021Rheumatoid ArthritisPsoriatic Arthritis
